Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera Inc (NASDAQ:NTRA) CEO Sells $200,565.00 in Stock
05:58am, Saturday, 20'th Jun 2020
Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,457 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $45.00, f
Deutsche Bank AG Sells 472 Shares of Natera Inc (NASDAQ:NTRA)
06:44am, Friday, 19'th Jun 2020
Deutsche Bank AG lessened its position in shares of Natera Inc (NASDAQ:NTRA) by 0.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commi
The Global Breast Cancer Liquid Biopsy Testing Devices Market will grow by USD 479.83 mn during 2020-2024
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing
01:05pm, Thursday, 18'th Jun 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and BESPOKE CRC trials, with both studies experienci
Global Non-Invasive Prenatal Testing Market Assessment 2020-2025 - ResearchAndMarkets.com
12:00am, Thursday, 18'th Jun 2020
The
Natera Files Patent Suit Against Progenity, Inc.
04:22pm, Wednesday, 17'th Jun 2020
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, filed suit today against Progenity, Inc. for infringing six patents: U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 1
Edited Transcript of NTRA earnings conference call or presentation 6-May-20 8:30pm GMT
06:45am, Tuesday, 09'th Jun 2020
Q1 2020 Natera Inc Earnings Call
Here is What Hedge Funds Think About Natera Inc (NTRA)
03:35pm, Friday, 05'th Jun 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Moving Average Crossover Alert: Natera
02:00pm, Tuesday, 02'nd Jun 2020
Natera, Inc. (NTRA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights
01:07pm, Monday, 01'st Jun 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the launch of a novel technique to enhance results from the Prospera donor-derived cell-free D
Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA
03:08pm, Tuesday, 26'th May 2020
SAN CARLOS, Calif., May 26, 2020 /PRNewswire via COMTEX/ --
SAN CARLOS, Calif., May 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and...
Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA
02:08pm, Tuesday, 26'th May 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
01:03pm, Tuesday, 19'th May 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and its collaborators will present new data demonstrating the clinical validity and utility of its personalized molec
Natera and Illumina Settle Patent Dispute
01:03pm, Monday, 18'th May 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announced that they
Natera to Present at the UBS Virtual Global Healthcare Conference
01:03pm, Wednesday, 13'th May 2020
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the UBS Virtual Global Healthcare Conference on Monday, M
